Group 1 - The National Healthcare Security Administration announced the inclusion of Kangbaxipu Eye Injection (brand name "Langmu") in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, recognizing its innovation and clinical value [1][2] - Kangbaxipu is currently the only domestic innovative drug covering four major indications for retinal diseases, which will enhance the stability and accessibility of medication for patients [1] - The new drug catalog will be implemented starting January 1, 2026, but the specific impact on the company's current operating performance cannot be accurately estimated at this time [1]